SP1‐Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer
Advanced Science · 2025-11 · 12 (42)
DOI: 10.1002/advs.202510071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.08.2025. Verfasst von Hexing Hang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jian…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Sp1 Transcription Factor, Glycolysis, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, commonly progressing from pancreatic intraepithelial neoplasia (PanIN). However, the molecular alterations in PanIN lesions and their contribution to PDAC progression remain poorly defined. Here, using laser capture microdissection‐based proteomics of patient tissues, early metabolic remodeling and upregulation of the transcriptional factor specificity protein 1 (SP1) in PanIN lesions are identified, which persisted into the PDAC stage. That SP1 overexpression promoted PDAC proliferation is demonstrated in patient‐derived organoid xenograft models (PDOXs), while deletion of Sp1 inhibited tumorigenesis and progression in a transgenic mouse model of PDAC ( Kras LSL‐G12D/+ ; Trp53 LSL‐R172H/+ ; Sp1 LOXP/LOXP ; Pdx1‐Cre ). ChIP‐seq and isotope tracing revealed that SP1 enhances aerobic glycolysis by transcriptionally activating 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase (PFKFB4), a key regulator of glycolysis. Combination therapy targeting SP1 and PFKFB4 demonstrated significant efficacy in PDAC models in vivo. The findings suggest that SP1 is a critical regulator of PDAC initiation and progression through its control of metabolic remodeling. Targeting SP1 and PFKFB4 represents a promising therapeutic strategy for PDAC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210008, China.
- Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210008, China.
- Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, Jiangsu, 210093, China.
- The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, 211100, China.
- Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, 210093, China.
- Clinical and Translational Research Center, Affiliated Hospital of Nantong University & Department of Oncology, Medical School of Nantong University, Nantong, Jiangsu, 226007, China.
ORCID-Profile: Hexing Hang
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Hang, H., Yu, M., Zhu, L., Tang, N., Fu, X., Cai, Z., Yan, M., Chen, Y., Yang, L., Wu, J., Tang, J., Xie, Y., Li, Q., Fu, X., Mao, L., Chen, J., Meng, F., Kong, B., Han, X., …, & Cheng, H. (2025). SP1‐Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Advanced Science, 12(42). https://doi.org/10.1002/advs.202510071
Vancouver
Hang H, Yu M, Zhu L, Tang N, Fu X, Cai Z, et al. SP1‐Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Advanced Science. 2025;12(42). doi:10.1002/advs.202510071
BibTeX
@article{Hang2025,
author = {Hang, Hexing and Yu, Mengyu and Zhu, Linxi and Tang, Neng and Fu, Xiao and Cai, Zhenghua and Yan, Minghao and Chen, Yi and Yang, Lei and Wu, Jianzhuang and Tang, Jiatong and Xie, Yu and Li, Qi and Fu, Xu and Mao, Liang and Chen, Jun and Meng, Fanqing and Kong, Bo and Han, Xiaodong and Yan, Chao and Qiu, Yudong and Cheng, Hao},
title = {SP1‐Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {42},
doi = {10.1002/advs.202510071}
}
EUVIMED